9 research outputs found
Production of Medical Radioisotopes with High Specific Activity in Photonuclear Reactions with Beams of High Intensity and Large Brilliance
We study the production of radioisotopes for nuclear medicine in
photonuclear reactions or ()
photoexcitation reactions with high flux [()/s], small
diameter m and small band width () beams produced by Compton back-scattering of laser
light from relativistic brilliant electron beams. We compare them to (ion,np) reactions with (ion=p,d,) from particle accelerators like
cyclotrons and (n,) or (n,f) reactions from nuclear reactors. For
photonuclear reactions with a narrow beam the energy deposition in the
target can be managed by using a stack of thin target foils or wires, hence
avoiding direct stopping of the Compton and pair electrons (positrons).
isomer production via specially selected cascades
allows to produce high specific activity in multiple excitations, where no
back-pumping of the isomer to the ground state occurs. We discuss in detail
many specific radioisotopes for diagnostics and therapy applications.
Photonuclear reactions with beams allow to produce certain
radioisotopes, e.g. Sc, Ti, Cu, Pd, Sn,
Er, Pt or Ac, with higher specific activity and/or
more economically than with classical methods. This will open the way for
completely new clinical applications of radioisotopes. For example Pt
could be used to verify the patient's response to chemotherapy with platinum
compounds before a complete treatment is performed. Also innovative isotopes
like Sc, Cu and Ac could be produced for the first time
in sufficient quantities for large-scale application in targeted radionuclide
therapy.Comment: submitted to Appl. Phys.
Indication for different mechanisms of kidney uptake of radiolabeled peptides.
Contains fulltext :
51440.pdf (publisher's version ) (Closed access)Nephrotoxicity due to renal reabsorption of radiolabeled peptides limits the tumor dose in peptide receptor radiotherapy (PRRT). Therefore, we evaluated the ability of several agents to inhibit the renal accumulation of different radiopeptides. METHODS: Male Wistar rats (4 per group) were injected intravenously with 1 MBq of (111)In-labeled octreotide (OCT), minigastrin (MG), bombesin (BOM), or exendin (EX), together with a potential inhibitor of renal uptake (lysine [Lys], poly-glutamic acid [PGA], and Gelofusine [GF], a gelatin-based plasma expander) or phosphate-buffered saline as a control. Organ uptake at 20 h after injection was determined as the percentage of injected activity per gram (%IA/g). Lys, PGA, and GF were also combined to determine whether an additive effect could be obtained. The localization of the peptides in the kidneys was investigated by autoradiography using a phosphor imager. RESULTS: OCT accumulation in the kidney was inhibited by Lys and GF (40.7%-45.1%), whereas PGA was ineffective. On the other hand, renal uptake of BOM, MG, and EX was inhibited by PGA and GF (15.4%-85.4%), whereas Lys was ineffective. The combination of GF and Lys showed additive effects in inhibiting OCT uptake, whereas PGA and GF had additive effects for the inhibition of EX uptake. The amount of kidney uptake correlated with the number of charged amino acids. All radiopeptides were localized in the renal cortex, as indicated by autoradiography. CONCLUSION: Inhibition of renal accumulation of the radiopeptides tested could be achieved by either Lys or PGA but not by both at the same time, suggesting 2 different uptake mechanisms. The differences in renal accumulation of radiopeptides may be related to the number of charges of a molecule. GF is the only compound that inhibited renal accumulation of all radiopeptides tested. Additional experiments are needed to further elucidate these findings and to optimize inhibition of renal accumulation of radiopeptides to reduce the kidney dose in PRRT
Local Trageting of Malignant Gliomas by the Difussible Peptidic Vector DOTAGA-substance P
Purpose: Malignant glial brain tumors consistentlyo verexpress neurokinin type 1receptors. In classic seed-based brachytherapy, one to several rigid 125I seeds are inserted, mainlyf or the treatment of small low-grade gliomas. The complex geometryo f rapidly proliferating high-grade gliomas requires a diffusible system targeting tumor-associated surface structures to saturate the tumor, including its margins.JRC.E.5-Nuclear chemistr
Targeted therapy in nuclear medicine--current status and future prospects.
Contains fulltext :
53512.pdf (publisher's version ) (Closed access)In recent years, a number of new developments in targeted therapies using radiolabeled compounds have emerged. New developments and insights in radioiodine treatment of thyroid cancer, treatment of lymphoma and solid tumors with radiolabeled monoclonal antibodies (mAbs), the developments in the application of radiolabeled small receptor-specific molecules such as meta-iodobenzylguanidine and peptides and the position of locoregional treatment in malignant involvement of the liver are reviewed. The introduction of recombinant human thyroid-stimulating hormone and the possibility to enhance iodine uptake with retinoids has changed the radioiodine treatment protocol of patients with thyroid cancer. Introduction of radiolabeled mAbs has provided additional treatment options in patients with malignant lymphoma, while a similar approach proves to be cumbersome in patients with solid tumors. With radiolabeled small molecules that target specific receptors on tumor cells, high radiation doses can be directed to tumors in patients with disseminated disease. Radiolabeled somatostatin derivatives for the treatment of neuroendocrine tumors are the role model for this approach. Locoregional treatment with radiopharmaceuticals of patients with hepatocellular carcinoma or metastases to the liver may be used in inoperable cases, but may also be of benefit in a neo-adjuvant or adjuvant setting. Significant developments in the application of targeted radionuclide therapy have taken place. New treatment modalities have been introduced in the clinic. The concept of combining therapeutic radiopharmaceuticals with other treatment modalities is more extensively explored